Tirzepatide CAS NO.2023788-19-2

Tirzepatide

• ‌Dual Mechanism of Action‌
• Tirzepatide is the first drug to target GIP and GLP-1 receptors, providing a dual mechanism of action. GIP enhances insulin secretion, improves insulin sensitivity, and may help reduce fat accumulation; GLP-1 promotes insulin secretion after meals, reduces appetite, slows gastric emptying, and reduces glucagon secretion, thereby helping to regulate blood sugar levels.
• ‌Significant Blood Sugar Lowering Effect‌
• Tirzepatide performs well in controlling blood sugar and is superior to other diabetes drugs, including GLP-1 receptor agonists (such as semaglutide) and insulin. It activates GIP and GLP-1 receptors, enhances insulin secretion, reduces glucagon secretion, and improves overall glucose metabolism‌
• ‌Significant Weight Loss‌
• Tirzepatide can help obese or overweight individuals lose significant weight, even in the absence of diabetes. Clinical trials have shown that patients treated with Tirzepatide lost more than 10% of their body weight, which is more significant than other treatments. This weight loss effect is mainly due to its effect on appetite, satiety and gastric emptying rate, which helps reduce food intake. ‌
• ‌Improve cardiovascular health‌
• Tirzepatide also has a positive effect on improving cardiovascular health. Some clinical trials have shown that patients treated with Tirzepatide have a certain degree of decrease in systolic and diastolic blood pressure, which can reduce the risk of heart disease and stroke. In addition, Tirzepatide can improve lipid profiles, reduce LDL cholesterol and increase HDL cholesterol. ‌
• ‌Wide range of indications‌
• Tirzepatide is not only used to treat diabetes and obesity, but is also conducting clinical trials for indications related to metabolic abnormalities, such as sleep apnea syndrome, heart failure and non-alcoholic steatohepatitis (NASH). ‌